Page last updated: 2024-10-30

mesalamine and Cardiovascular Diseases

mesalamine has been researched along with Cardiovascular Diseases in 2 studies

Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.

Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.

Research Excerpts

Excerpt	Relevance	Reference
"The anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis."	5.19	The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. ( Abdel-Mohsen, M; Albright, R; Cohen, M; Deeks, SG; Dunham, RM; Gorelick, R; Hsue, PY; Huang, Y; Hunt, PW; Liegler, T; Lifson, J; Martin, JN; McCune, JM; Piatak, M; Somsouk, M; Wu, Y, 2014)

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Somsouk, M	1
Dunham, RM	1
Cohen, M	1
Albright, R	1
Abdel-Mohsen, M	1
Liegler, T	1
Lifson, J	1
Piatak, M	1
Gorelick, R	1
Huang, Y	1
Wu, Y	1
Hsue, PY	1
Martin, JN	1
Deeks, SG	1
McCune, JM	1
Hunt, PW	1
Savoye, G	1

Clinical Trials (2)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Effect of Interferon Alpha 2b Intensification on HIV-1 Residual Viremia in Individuals Suppressed on Antiretroviral Therapy[NCT01295515]	Phase 1/Phase 2	7 participants (Actual)	Interventional	2011-02-11	Completed
Mesalamine to Reduce T Cell Activation in HIV Infection[NCT01090102]	Phase 4	33 participants (Actual)	Interventional	2010-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Count of Participants With Serious and Non-serious Adverse Events Assessed by the Division of Acquired Immune Deficiency Syndrome (AIDS) Table for Grading Adult Adverse Events.

Here is the count of participants with serious and non-serious adverse events assessed by the Division of Acquired Immune Deficiency Syndrome (AIDS) Table for Grading Adult Adverse Events for severity (mild/moderate/severe), expectedness (expected/unexpected), and relatedness to study drug (definitely, probably, possibly, unlikely, or unrelated). (NCT01295515)
Timeframe: Date consent signed to date off study, approximately 66 months and 2 days.

Intervention	Participants (Count of Participants)
Interferon Treatment	7

Fold Change in Ribonucleic Acid (RNA) and Deoxyribonucleic Acid (DNA) in Human Immunodeficiency Virus Type 1 (HIV-1) Genetic Variation in Individuals Undergoing Interferon Therapy

The outcome measure is the fold change in the ratio of HIV RNA to HIV DNA. For the pre and post interferon time point, the level of HIV RNA is divided by the level of HIV DNA and this ratio of the HIV RNA/DNA pre and post interferon is calculated to yield the fold change in HIV RNA/DNA levels. Fold change does not have units. (NCT01295515)
Timeframe: week 4 (post) and week 0 (pre)

Intervention	fold change (Number)
	Patient #1	Patient #2	Patient #3	Patient #4	Patient #5	Patient #6	Patient #7
Interferon Treatment	0.408	1.44	0.684	1.12	2.24	4.37	1.05

Pre- and Post- Interferon Alpha on Human Immunodeficiency Virus Type 1 (HIV-1) Deoxyribonucleic Acid (DNA)

Cell associated HIV nucleic acid levels were measured using a single copy assay, and numbers of cells were quantified using a polymerase chain reaction method that detects C-C chemokine receptor type 5 (CCR5) DNA. (NCT01295515)
Timeframe: week 4 (post) compared to week 0 (pre)

Intervention	# of copies of DNA/million cells (Number)
	Patient #1 HIV DNA Pre	Patient #1 HIV DNA Post	Patient #2 HIV DNA Pre	Patient #2 HIV DNA Post	Patient #3 HIV DNA Pre	Patient #3 HIV DNA Post	Patient #4 HIV DNA Pre	Patient #4 HIV DNA Post	Patient #5 HIV DNA Pre	Patient #5 HIV DNA Post	Patient #6 HIV DNA Pre	Patient #6 HIV DNA Post	Patient #7 HIV DNA Pre	Patient #7 HIV DNA Post
Interferon Treatment	1200	790	150	150	660	500	400	310	10	19	520	420	390	460

Pre- and Post- Interferon Alpha on Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA)

Cell associated HIV nucleic acid levels were measured using a single copy assay, and numbers of cells were quantified using a polymerase chain reaction method that detects RNA. (NCT01295515)
Timeframe: week 4 (post) compared to week 0 (pre)

Intervention	# of copies of HIV RNA/million cells (Number)
	Patient #1 HIV RNA Pre	Patient #1 HIV RNA Post	Patient #2 HIV RNA Pre	Patient #2 HIV RNA Post	Patient #3 HIV RNA Pre	Patient #3 HIV RNA Post	Patient #4 HIV RNA Pre	Patient #4 HIV RNA Post	Patient #5 HIV RNA Pre	Patient #5 HIV RNA Post	Patient #6 HIV RNA Pre	Patient #6 HIV RNA Post	Patient #7 HIV RNA Pre	Patient #7 HIV RNA Post
Interferon Treatment	670	180	90	130	810	420	450	390	12	51	850	300	250	310

Pre-and Post- Plasma Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) in HIV-infected Individuals

The outcome measure is copies of HIV RNA per ml of plasma. HIV RNA levels are measured using a polymerase chain reaction method. (NCT01295515)
Timeframe: week 4 (post) compared to week 0 (pre)

Intervention	copies/ml (Median)
	Patient #1 Pre	Patient #1 Post	Patient #2 Pre	Patient #2 Post	Patient #3 Pre	Patient #3 Post	Patient #4 Pre	Patient #4 Post	Patient #6 Pre	Patient #6 Post	Patient #7 Pre	Patient #7 Post
Interferon Treatment	0.7	3.8	0.2	.02	3.8	0.8	.02	1.5	1.3	0.36	9.1	8.8

Log(10) Change in % Activated (CD38+HLA-DR+)CD8+ T Cells After Treatment Crossover

Log(10) change in the percentage of activated T cells during the second 12 weeks of the study (NCT01090102)
Timeframe: Week 12, Week 24

Intervention	Log10(percentage of T cells) (Mean)
Mesalamine Then Placebo	0.003
Placebo Then Mesalamine	-0.03

Log(10) Change in % Activated (CD38+HLA-DR+)CD8+ T Cells During the First 12 Weeks of Study

(NCT01090102)
Timeframe: Week 0, Week 12

Intervention	Log10(percentage of T cells) (Mean)
Mesalamine Then Placebo	0.03
Placebo Then Mesalamine	-0.01

Trials

1 trial available for mesalamine and Cardiovascular Diseases

Article	Year
The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. PloS one, 2014, Volume: 9, Issue:12 Topics: Biomarkers; Brachial Artery; Cardiovascular Diseases; CD4-Positive T-Lymphocytes; Cross-Over Studies	2014
The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. PloS one, 2014, Volume: 9, Issue:12 Topics: Biomarkers; Brachial Artery; Cardiovascular Diseases; CD4-Positive T-Lymphocytes; Cross-Over Studies	2014
The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. PloS one, 2014, Volume: 9, Issue:12 Topics: Biomarkers; Brachial Artery; Cardiovascular Diseases; CD4-Positive T-Lymphocytes; Cross-Over Studies	2014
The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. PloS one, 2014, Volume: 9, Issue:12 Topics: Biomarkers; Brachial Artery; Cardiovascular Diseases; CD4-Positive T-Lymphocytes; Cross-Over Studies	2014

Other Studies

1 other study available for mesalamine and Cardiovascular Diseases

Article	Year
Ulcerative colitis and PPAR gamma ligand. Is cardiac toxicity on the other side of the coin? The American journal of gastroenterology, 2008, Volume: 103, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Colitis, Ulcerative; Humans; Ligan	2008